Mimedx Group Financial Results
MiMedx Group reported Q3 2026 financial results, highlighting a 45% year-over-year revenue decline to $62 million primarily due to Medicare reimbursement changes affecting its Wound business. Despite the overall decline, the Surgical franchise grew 9% and the company returned to positive Adjusted EBITDA following cost-reduction initiatives.
“Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.”
Joseph H. Capper, MIMEDX Chief Executive Officer
“We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech. As we prepare for the combination of the two companies, our conviction in both the strategic rationale and the financial merits of this transaction remains strong,”
Joseph H. Capper, MIMEDX Chief Executive Officer